Skip to main content
Premium Trial:

Request an Annual Quote

CuraGen Revenues Down, Losses Up in Q1

NEW YORK, April 26-CuraGen said yesterday that revenues had  slipped and net loss had nearly quadrupled for the first quarter of 2002.


For the quarter ended March 31, 2002, the company reported revenues of $4.8 million, down 16 percent from the equivalent quarter last year.


R&D was up 66 percent to $20.1 million as compared to the same reporting period in 2001.


CuraGen's net loss for the quarter was $19.6 million or 40 cents per common share. For Q1 in 2001, its loss was $5.4 million or 11 cents per share.


The company also reported cash resources and short-term investments of about $478 million.


CuraGen hopes to file its first IND with the Food & Drug Administration within six to 12 months.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.